Krebs Biochemicals & Industries Ltd (KREBSBIO) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Krebs Biochemicals & Industries Ltd on NSE and BSE, with an AI summary of each filing.
Krebs Biochemicals and Industries Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 29 Oct 2026, 6:40 pm
Financial Results for the quarter ended 30.09.2026
Financial Result · 29 Oct 2026, 6:36 pm
Outcome of the Board Meeting for consideration of unaudited financial results for the quarter ended 30.09.2026
Outcome · 29 Oct 2026, 6:30 pm
Krebs Biochemicals & Industries Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lacs) ■ Revenue: 579 (+38.9% YoY | -17.1% QoQ) ■ EBITDA: -193 (+30.9% YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): -33.3 (+3369 bps YoY | Profit to Loss QoQ) ■ PAT: -540 (+12.1% YoY | -117.3% QoQ) ■ EPS (INR): -2.50 (+12.3% YoY | -117.4% QoQ)
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
Intimation · 29 Oct 2026, 5:30 am
KREBS BIOCHEMICALS AND INDUSTRIES LIMITED has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 29 Oct 2026, 5:30 am
Krebs Biochemicals & Industries Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve The Company ....
Intimation · 29 Oct 2026, 5:30 am
Krebs Biochemicals Schedules Board Meeting for Q2 FY27 Financial Results Krebs Biochemicals & Industries Limited announced that its Board of Directors will meet on 29th Oct'26 to consider and adopt the unaudited financial results for the second quarter and half year ended 30th Sep'26. In accordance with SEBI insider trading regulations, the trading window for dealing in company securities has been closed from the close of business hours on 30th Sep'26 and will remain closed until 48 hours following the declaration of the financial results.
Scrutinizer Report of 34th AGM
Annual General Meeting · 30 Sept 2026, 12:38 am
Outcome of 34th AGM
Annual General Meeting · 29 Sept 2026, 6:06 pm
The Company has enclosed herewith Notice of 34th AGM along with Annual Report FY 2025-26.
Annual General Meeting · 04 Sept 2026, 8:29 pm
We are enclosing herewith copy of Annual Report for the financial year ended 31st March 2026.
Others (Uncategorized) · 04 Sept 2026, 4:58 pm
Results for the quarter ended 30602026
Financial Result · 06 Aug 2026, 7:20 pm
Krebs Reports Widening Q1FY27 Loss Amid Plant Closure and Pending Amalgamation Krebs Biochemicals reported a net loss of ₹248.48 lacs for Q1FY27, widening from a loss of ₹233.96 lacs QoQ. Revenue from operations increased 2.5% QoQ to ₹698.35 lacs, but total income fell 19% QoQ to ₹714.00 lacs. Total expenses decreased 13.7% QoQ to ₹962.48 lacs. Operations at its Vizag unit remain closed following a pollution control board order. The Board approved the amalgamation with Ipca Laboratories on 26 Jun'26, with an appointed date of 01 Apr'26, subject to approvals.
Outcome of BM
Outcome · 06 Aug 2026, 7:12 pm
Krebs Biochemicals & Industries Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lacs) ■ Revenue: 698 (+27.4% YoY | +2.6% QoQ) ■ EBITDA: 82.7 (Loss to Profit YoY | Loss to Profit QoQ) ■ EBITDA Margin (%): 11.8 (Loss to Profit YoY | Loss to Profit QoQ) ■ PAT: -248 (+53.3% YoY | -6.2% QoQ) ■ EPS (INR): -1.15 (+53.4% YoY | -5.5% QoQ)
Krebs Biochemicals & Industries Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve Intimation ....
Intimation · 06 Aug 2026, 5:30 am
Krebs Biochemicals Board Meeting Scheduled for Q1 FY27 Results Krebs Biochemicals & Industries Limited has scheduled a Board of Directors meeting on Thu, Aug 6, 2026. The agenda includes consideration and adoption of the unaudited financial results for the first quarter ending Jun 30, 2026. The trading window for insiders will remain closed from the close of business on Jun 30, 2026, until 48 hours after the results are declared. This is in compliance with SEBI's insider trading regulations.
outcome of Baorad meeting
Others (Uncategorized) · 26 Jun 2026, 6:49 pm
Outcome of Board Meeting
Others (Uncategorized) · 26 Jun 2026, 6:41 pm
Audited Results for fiancial yaer ended 31.03.2026
Financial Result · 21 May 2026, 6:57 pm
Krebs Biochemicals FY26 Loss Narrows Amidst Manufacturing Unit Closure Krebs Biochemicals reported a narrower net loss of Rs 1,693.31 lacs for FY26, an improvement from Rs 2,693.93 lacs in FY25. Revenue from operations for FY26 declined 45.2% YoY to Rs 2,373.16 lacs. For Q4 FY26, revenue was Rs 680.91 lacs with a net loss of Rs 233.96 lacs. Operations at the Vizag manufacturing unit remained closed following a Pollution Control Board order dated 7th Feb'25. The company's net worth stood at negative Rs 16,275.48 lacs as of 31st Mar'26.
Outcome of Board Meeting 21.05.2026
Outcome · 21 May 2026, 6:52 pm
Krebs Biochemicals & Industries Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lacs) ■ Revenue: 681 (+11.6% YoY | -6.4% QoQ) ■ EBITDA: -86.8 (+84.0% YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): -12.7 (+7590 bps YoY | Profit to Loss QoQ) ■ PAT: -234 (+71.7% YoY | +25.2% QoQ) ■ EPS (INR): -1.09 (+71.5% YoY | +24.8% QoQ)
Krebs Biochemicals & Industries Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve Pursuant to ....
Intimation · 21 May 2026, 5:30 am
Krebs Biochemicals Schedules Board Meeting for Q4 and FY26 Results Krebs Biochemicals & Industries Ltd has scheduled a Board of Directors meeting on 21 May'26 to consider and approve the audited financial results for the fourth quarter and financial year ended 31 Mar'26. The trading window for insiders, which closed on 31 Mar'26, will reopen 48 hours after the declaration of these results.
Clarification on price movement
Others (Uncategorized) · 10 Apr 2026, 3:41 pm
Krebs Biochemicals Responds to BSE Query on Price Movement Krebs Biochemicals & Industries, in a letter dated Apr 10, '26, responded to a BSE clarification request regarding significant share price movement. The company stated there is no material information or undisclosed event under SEBI's Regulation 30 that would have a bearing on the security's price. Management affirmed it complies with all disclosure requirements and has been regularly disseminating relevant information. This response follows a BSE inquiry dated Apr 8, '26, about the stock's recent volatility.
The Exchange has sought clarification from Krebs Biochemicals & Industries Ltd on April 8, 2026 with reference to significant movement in price, in order to ensure that investors have latest ....
Others (Uncategorized) · 09 Apr 2026, 12:36 am
Result for the quarter ended 31.12.2025
Financial Result · 09 Feb 2026, 7:09 pm
Krebs Biochemicals Reports Widening Q3FY26 Loss on Lower Revenue Krebs Biochemicals & Industries posted a net loss of Rs. 312.65 lacs for Q3FY26, wider than the Rs. 614.28 lacs loss in Q2FY26 but narrower than the Rs. 773.89 lacs loss YoY. Revenue from operations for the quarter ended 31 Dec'25 stood at Rs. 727.42 lacs, a significant 74.4% QoQ increase but a 36.6% YoY decline. For the nine months, the net loss widened to Rs. 1,459.35 lacs from Rs. 1,867.09 lacs YoY. Basic EPS for Q3 was negative at Rs. (1.45).
Outcome of Board Meeting
Outcome · 09 Feb 2026, 7:05 pm
Krebs Biochemicals & Industries Limited - Financial Result for the Quarter ended 31st Dec'25 (Standalone, INR Lacs) ■ Revenue: 727 (-36.6% YoY | +74.6% QoQ) ■ EBITDA: 29.7 (Loss to Profit YoY | Loss to Profit QoQ) ■ EBITDA Margin (%): 4.1 (Loss to Profit YoY | Loss to Profit QoQ) ■ PAT: -313 (+59.6% YoY | +49.1% QoQ) ■ EPS (INR): -1.45 (+59.6% YoY | +49.1% QoQ)
Krebs Biochemicals & Industries Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2026 ,inter alia, to consider and approve Board Meeting ....
Intimation · 09 Feb 2026, 5:30 am
Krebs Biochemicals Schedules Board Meeting for Q3 FY26 Results Krebs Biochemicals & Industries will hold a Board of Directors meeting on 09 Feb'26 to consider and adopt the unaudited financial results for the third quarter and nine months ended 31 Dec'25. The trading window for insiders, which closed on 31 Dec'25, will remain shut until 48 hours after the results are declared. This meeting is a key event for shareholders awaiting the company's Q3 financial performance update.
The Company has enclosed herewith report on relodgement of shares for the month of December 2025.
Others (Uncategorized) · 05 Jan 2026, 3:47 pm
Krebs Biochemicals Reports No Physical Share Re-lodgement Requests Krebs Biochemicals & Industries, via its RTA KFIN Technologies, reported NIL requests for the re-lodgement of physical share transfers for the month ended Dec 31, 2025. The filing is in accordance with the SEBI circular dated Jul 2, 2025. The company also noted that the special six-month window for shareholders to submit such requests remains open from Jul 7, 2025, to Jan 6, 2026. This indicates no physical share transfer activity was processed under the special provision during December.
The Company enclosing herewith RTA report on relodgement of trasnfer request of physical shares for the month Nov 2025.
Others (Uncategorized) · 03 Dec 2025, 6:18 pm
Krebs Biochemicals Reports on Physical Share Transfer Re-lodgement Window Krebs Biochemicals & Industries Limited has informed exchanges about the status of re-lodgement requests for physical shares as of 30th Nov'25. According to a report from its Registrar and Share Transfer Agent, KFIN Technologies, there were no requests received, processed, approved, or rejected during the month. This is in compliance with a SEBI circular dated 2nd Jul'25, which established a special six-month window for shareholders to re-lodge transfer requests. The window is open from 7th Jul'25 until 6th Jan'26.